Seegene Unveils Revolutionary Unattended PCR Automation at ADLM 2025 Conference

Seegene's Groundbreaking PCR Automation System

In a significant advancement in the field of molecular diagnostics, Seegene Inc. proudly presented its revolutionary CURECA™ system during the ADLM 2025 conference held in Chicago from July 28 to 31. This pioneering unattended PCR automation system is set to transform the diagnostic landscape by completely automating the entire PCR testing process, thus minimizing human error and maximizing efficiency.

Automation at Every Stage of PCR Testing

CURECA™ stands as the world’s first fully automated PCR testing system, designed to operate 24/7 without human intervention. This remarkable technology streamlines every stage of PCR testing—from sample storage and pre-treatment to nucleic acid extraction, amplification, and analysis of results. By eliminating the human factor, CURECA™ enhances consistency and reliability in test outcomes, ensuring that laboratories can deliver accurate diagnostics consistently.

At the heart of this automation is a fully automated preparation module which tackles one of the most labor-intensive and error-prone steps in laboratory workflows—pre-processing samples. Traditional sample preparation, especially with varying types such as urine, blood, sputum, and stool, has often posed challenges in terms of accuracy and efficiency. Lab technicians typically engage in repetitive manual tasks that can lead to inconsistencies due to varying levels of expertise among personnel.

Stool samples, in particular, present considerable hurdles for automation due to their viscosity and solid content, often requiring labor-intensive manual intervention. The CURECA™ preparation module overcomes this by fully automating the pre-processing of all major sample types, including stool, thereby eliminating long-standing barriers in laboratory practice. This innovation not only reduces labor costs but also increases the system's throughput while improving overall operational and economic efficiency.

As a result, laboratory personnel can transition from manual tasks to more strategic activities, such as data analysis and clinical interpretation of results. This ensures that staff are better utilized, especially in high-volume environments that require continuous testing and maintain high standards of accuracy and quality in results.

This preparation module is not solely limited to PCR diagnostics; it also supports pre-processing in other domains such as clinical chemistry and immunological analysis. This makes it a significant leap forward in automation across the broader diagnostics service market. Moreover, its modular architecture allows for flexible configuration and deployment according to each laboratory's size, layout, and specific needs.

STAgora™ Enhances Personalized Healthcare

In conjunction with CURECA™, Seegene also introduced its STAgora™ platform at the ADLM 2025 conference. This real-time statistical platform aggregates PCR diagnostic data to support clinical decision-making. By collecting data from hospitals worldwide, STAgora™ provides integrated insights into regional infection trends, hospital positivity rates, and co-infection patterns. It offers over 40 statistical tools tailored for clinical support, enabling healthcare providers to compare individual patient results against local and regional epidemiological data. This leads to more accurate, statistically sound treatment strategies.

Through STAgora™, doctors can assess infection trends at both patient and community levels, enhancing the precision and speed of diagnostics and healthcare planning. The swift and reliable results generated from this comprehensive analysis are poised to make STAgora™ a vital analytical tool for clinical decision-making.

Seeking Global Collaboration and Partnerships

Leveraging its presentation at ADLM 2025, Seegene aims to broaden access to CURECA™ and STAgora™, offering early pilot partnerships and forging new global alliances. The excitement surrounding CURECA™ was palpable earlier this year during the ESCMID Global 2025 conference, a leading European congress on clinical microbiology and infectious diseases.

To bolster its research and production capacity in the United States, Seegene has established local subsidiaries, including Seegene Technologies and Seegene CURECA.

As Daniel Shin, Executive Vice President and Head of Global Sales and Marketing at Seegene noted, “CURECA™ and STAgora™ are not merely diagnostic tools or software. They set a new global standard that will reshape diagnostics in clinical settings worldwide. We will continue to share numerous technological advancements that have been developed over the years and strive for fundamental innovations across the global diagnostic ecosystem.”

About Seegene

Seegene boasts 20 years of experience in R&D, manufacturing, and business operations related to syndromic PCR testing. This expertise proved invaluable during the COVID-19 pandemic, with the company delivering over 340 million tests across more than 100 countries. Seegene's real-time syndromic diagnostic technology allows simultaneous testing of specimens for 14 pathogens causing similar symptoms, offering quantitative assessments.

For more information, visit Seegene.com and follow them on LinkedIn.